KALV Overview

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.

Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is34.38 USD with a low forecast of 29.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kalvista Pharmaceuticals Inc revenue for the last quarter amounts to 40.86M USD, increased 15.48

Kalvista Pharmaceuticals Inc. EPS for the last quarter amounts to -0.43 USD, decreased -148.31

Kalvista Pharmaceuticals Inc (KALV) has 275 emplpoyees as of May 31 2026.

Today KALV has the market capitalization of 1.43B USD.